Guggenheim analyst Seamus Fernandez lowered the firm’s price target on Tenax Therapeutics (TENX) to $15 from $16 and keeps a Buy rating on the shares. The firm, which is updating its model following the company’s Q1 results, looks forward to the Phase 3 LEVEL readout in 2026. The firm believes this data will be “a major catalyst from which we see the potential for at least a 2x stock move from current levels,” the analyst added.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TENX:
- Tenax Therapeutics reports Q1 EPS (28c), consensus (41c)
- Tenax Therapeutics sees cash, equivalents funding company through 2027
- Tenax Therapeutics Advances Cardiopulmonary Therapies
- Tenax Therapeutics files to sell 4.14M shares of common stock for holders
- Tenax Therapeutics reports Q4 EPS (18c), consensus (43c)